Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2012

View Archived Issues

Promising data presented from phase II Cinryze combination trial

GeoVax obtains FDA approval to advance adjuvanted HIV vaccine to clinic

Studies address suitability of allopregnanolone to treat Niemann-Pick disease type C

GM-CSF-adjuvanted vaccine provides long-term protection in HIV model

Hadasit Bio-Holdings to receive further funding from Israeli government

FDA approves first cell-based product made from allogeneic human cells and bovine collagen

Immunogenicity and favorable tolerability reported for H5N1 flu vaccine

New data reported on biOasis immunoconjugate for HER2+ breast cancer

Epistem and GlaxoSmithKline enter biomarker collaboration

Enrollment begins in phase I RX-3117 trial

Calcium channel blocker for hypertension clear to enter clinical testing in China

PX'Therapeutics begins phase I trial of HIV vaccine

Calzada subsidiary discloses encouraging in vitro data on AOD-9603

Hybrigenics clear to conduct phase II inecalcitol study in CLL

Hutchison MediPharma reports new JAK inhibitors

Merck KGaA announces new inhibitors of FADK 1

Isotechnika and FDA reach SPA agreement on voclosporin trial

Novel caspase inhibitors discovered at Banyan Biomarkers

Phase I study of CBLB-502 advances

Novel apoptosis inducers prepared by U.S. university scientists

New Trevena G protein-biased mu opioid receptor ligand has analgesic activity

New RSV vaccines developed at GenVec

Phase III OMS-302 study meets endpoints

FDA accepts CRTX-080 NDA for filing

Attogen patents novel FGFR2IIIc-specific antibodies

Abbott identifies new potential analgesics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...